07.01.2019
- In the first major pharma deal of the year, Bristol-Myers Squibb (BMS) is to acquire biotech giant Celgene for $74 billion. The cash-and-stock transaction values the US biotech at...
17.04.2018
- For the global specialty chemicals sector, the past two years have been among the most exciting of the young millennium. Many mergers and acquisitions were in the spotlight in 2017...
06.04.2018
- In line with what it said were plans to modify its executive team structure “to enhance leadership focus on building the company for continued long-term success,” Celgene said its...
27.07.2017
- US pharmaceutical company Celgene has agreed to pay $280 million to settle a whistleblower lawsuit accusing it of fraud for promoting a thalidomide-based drug pair re-purposed to...
13.07.2017
- US biopharmaceutical company Celgene has agreed to buy a stake in China’s BeiGene and help to develop and commercialize that company’s investigational treatment for tumor cancers...
12.07.2017
- The US Food and Drug Administration (FDA) has placed a clinical hold on three phase 3 multiple myeloma studies testing US drugmaker Merck’s Keytruda (pembrolizumab) in combination...
14.06.2017
- US pharmaceutical giant Merck has announced it is suspending new enrollments in two phase 3 multiple myeloma studies with its blockbuster immunotherapy drug Keytruda (pembrolizumab...
24.02.2017
- In a letter to the leadership of the US Congress, 16 CEOs of major American companies, including Pfizer’s Ian Read, Eli Lilly’s David Ricks, Merck & Co’s Ken Frazier and Celgene’s...
